CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 54 enrolled
Drug / intervention
Sofosbuvir / Velpatasvir Oral Tablet [Epclusa] +1 moredrug
Likely dose
Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03801707
NCT03801707Phase 3Completed
CompareCT.gov

An Open Label, Proof of Concept Study to Evaluate the Feasibility and Safety of Kidney Transplant From HCV Positive Donors Into HCV Negative Recipient

Ohio State University·interventional·Posted Jan 11, 2019·Updated Sep 13, 2023

In Brief

A Phase 3 clinical trial evaluating Sofosbuvir / Velpatasvir Oral Tablet [Epclusa] and Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET] for Kidney Transplant and 2 related conditions. Completed, enrolled 54 participants across 1 site.

Detailed Summary

To evaluate the safety and feasibility of transplanting kidneys from Hepatitis C virus (HCV) infected donors into recipients without HCV infection

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Transplant, Hepatitis C, HCV
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedJan 11, 2019
Enrollment StartMar 22, 2019
Primary CompletionApr 28, 2021
Study CompletionApr 30, 2021
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 7.5 years ago

Interventions

Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]drug

fixed dose combination medication once a day for 12 weeks for the treatment of hepatitis C

Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]drug

Three tablets once a day for 12 weeks for treatment of hepatitis C